29 Cases of Primary Insomnia Treated by Superficial Needling at Zhenjing and Shangen Extra-Acupoints
Objective:To observe the curative effect of superficial needling at Zhenjing and Shangen extra-acupoints in the treat-ment of the primary insomnia,and to discuss its effect on adrenocorticotropic hormone(ACTH),cortisol(COR)and corticotropin releasing hormone(CRH)in the peripheral serum.Methods:60 outpatients with primary insomnia who were admitted to the Affili-ated Rehabilitation Hospital of Fujian University of Traditional Chinese Medicine from August 2022 to September 2023 were divid-ed into control group and observation group by random number table method,with 30 cases in each group.Finally,30 cases in con-trol group and 29 cases in observation group were completed in the study.Patients in the control group took one estazolam tablet orally 30 minutes before bedtime a day,7 days as a course of treatment,for a total of 2 courses.Patients in the observation group were treated by superficial needling at Zhenjing and Shangen extra-acupoints,5 times a week as a course of treatment,for a total of 2 courses with an interval of 2 days.The total scale and each scale of the pittsburgh sleep quality index(PSQI),the changes of ACTH,COR and CRH content in the peripheral serum were observed before and after treatment,and the curative effect between the two groups was compared.Results:Compared with those before treatment,the ACTH,COR and CRH content in the peripheral serum,the total scale and each scale of the PSQI decreased in the two groups(P<0.05).Compared with the control group,the daytime dys-function score decreased in the observation group(P<0.05).The total clinical efficiency was 75.86%in the observation group and 73.77%in the control group,there was no significant difference between the two groups(P>0.05).Conclusion:The superficial nee-dling is effective in treating primary insomnia,especially in the improvement of daytime dysfunction,and its mechanism may be related to the reduction of ACTH,COR,CRH content in the peripheral serum.